Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Hoffmann-La Roche
Azienda Ospedaliero-Universitaria di Parma
Abramson Cancer Center at Penn Medicine
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Washington University School of Medicine
Trishula Therapeutics, Inc.
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Massachusetts General Hospital
Cyteir Therapeutics, Inc.
Vector Vitale LLC
Zhejiang Provincial People's Hospital
Cedars-Sinai Medical Center
Celldex Therapeutics
OHSU Knight Cancer Institute
Corvus Pharmaceuticals, Inc.
Hoffmann-La Roche
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Hospital Universitario San Ignacio
Hospices Civils de Lyon
AstraZeneca
M.D. Anderson Cancer Center
First Affiliated Hospital of Wenzhou Medical University
National Cancer Institute (NCI)
Tocagen Inc.
Shenzhen BinDeBio Ltd.
Tel-Aviv Sourasky Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
sigma-tau i.f.r. S.p.A.
Incyte Corporation
Celgene
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
INSYS Therapeutics Inc
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alberta
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Novacea